MedTrace Logo

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

NCT06742736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13000

Last updated 2025-08-07

No results posted yet for this study

Summary

A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BGF

BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL

Sponsors & Collaborators

Principal Investigators

  • Michael Pollack, MS · AstraZeneca

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06742736 on ClinicalTrials.gov